GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (CHIX:ZEALc) » Definitions » Net Interest Income (for Banks)

Zealand Pharma AS (CHIX:ZEALC) Net Interest Income (for Banks)


View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma AS Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Zealand Pharma AS Business Description

Industry
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.